2025 CSCO：深耕肿瘤防治 正大天晴展示多瘤种创新成果

Core Insights - The 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO) showcased significant research findings on innovative cancer treatments, particularly focusing on the efficacy and safety of Anlotinib in various cancer types [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]. Non-Small Cell Lung Cancer (NSCLC) - Anlotinib combined with immune checkpoint inhibitors (ICIs) shows potential as an adjuvant therapy for non-pathological complete response (non-pCR) NSCLC patients post-neoadjuvant immunotherapy, with manageable safety profiles and promising disease-free survival [1]. - A prospective study indicates that the combination of Tislelizumab, Anlotinib, and chemotherapy is effective for resectable NSCLC, achieving a major pathological response (MPR) rate of 81.3% [2]. - Anlotinib combined with Pembrolizumab demonstrates efficacy in elderly patients with advanced PD-L1 positive NSCLC, with a median progression-free survival (PFS) of 8.2 months [3][4]. - The combination of Anlotinib, Pembrolizumab, and chemotherapy shows promising results in treating pulmonary sarcomatoid carcinoma, with an overall response rate (ORR) of 80% [5]. - Real-world data suggests that Anlotinib combined with PD-1/PD-L1 inhibitors is effective for advanced NSCLC, with a median PFS of 7.8 months and an overall survival (OS) of 17.0 months [6]. - A retrospective analysis indicates that Anlotinib combined with ICIs is a viable option for advanced NSCLC patients who have progressed after prior immunotherapy, showing an ORR of 28.6% [8]. Small Cell Lung Cancer (SCLC) - A study on the combination of liposomal Irinotecan, platinum-based chemotherapy, and Anlotinib for extensive-stage SCLC shows promising results, with a focus on maintaining treatment efficacy post-induction therapy [9]. - The combination of Surufatinib, albumin-bound Paclitaxel, and Anlotinib in second-line treatment for extensive-stage SCLC demonstrates a high ORR of 73.33% [10]. - Anlotinib combined with ICIs shows improved efficacy compared to Anlotinib alone in treating extensive-stage SCLC, with a median PFS of 6.5 months [11]. Gastrointestinal Tumors - Anlotinib combined with TAS-102 shows potential as a third-line treatment for metastatic colorectal cancer, with a DCR of 95% and a median PFS of 5.6 months [12]. - The combination of Anlotinib and chemoradiotherapy demonstrates significant efficacy in treating postoperative lymph node recurrence of esophageal squamous cell carcinoma, with a median PFS of 20.2 months [13]. Soft Tissue Sarcoma - Anlotinib combined with Cadonilimab shows promising results in advanced soft tissue sarcoma patients who have failed first-line treatment, with a median PFS of 6.9 months [14]. - The combination of Atezolizumab and Anlotinib in treating advanced liposarcoma and leiomyosarcoma shows a DCR of 89.5% [15]. Thyroid Cancer - Anlotinib combined with Sintilimab shows efficacy in treating BRAF wild-type anaplastic thyroid cancer, with an ORR of 47.6% and a median PFS of 9.63 months [17][18]. Other Cancers - The combination of Sintilimab and Anlotinib shows efficacy in treating advanced SMARCA4-deficient thoracic tumors, with an ORR of 51% [19]. - A real-world study indicates that prior treatment with Bevacizumab does not affect the efficacy of Anlotinib in treating solid tumors, with significant benefits observed in combination therapies [20]. Neutropenia Prevention - The Guard-04 study demonstrates that Aibegersit can effectively prevent chemotherapy-induced neutropenia in colorectal and pancreatic cancer patients, with manageable safety profiles [22].